Table 4.
Parameter, n (%) | Inotuzumab ozogamicin treatment | ||
---|---|---|---|
1.3 mg/m2 (n = 3) | 1.8 mg/m2 (n = 10) | Total (n = 13) | |
No. of patients with dose reductions | |||
No dose reductions | 3 (100) | 8 (80) | 11 (85) |
One or more dose reductions | 0 | 2 (20) | 2 (15) |
No. of dose reductions per patient* | |||
One | 0 | 2 (100) | 2 (15) |
Any adverse event leading to dose reduction† | 0 | 2 (20) | 2 (15) |
Thrombocytopenia | 0 | 1 (10) | 1 (8) |
Pleural effusion | 0 | 1 (10) | 1 (8) |
*Percentages are based on number of patients with ≥1 dose reduction in each treatment group. †Totals at a higher level are not necessarily the sum of those at the lower levels since a patient was able to report two or more different adverse events within the higher level category.